Trade Amgen - AMGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.39 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024901% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002679% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.35 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 317.28 |
| Open | 317.71 |
| 1-Year Change | 21.78% |
| Day's Range | 316.56 - 320.09 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Oct 4, 2024 | 319.54 | 1.96 | 0.62% | 317.58 | 320.57 | 316.02 |
| Oct 3, 2024 | 317.28 | 0.83 | 0.26% | 316.45 | 319.48 | 315.35 |
| Oct 2, 2024 | 319.47 | 1.69 | 0.53% | 317.78 | 320.44 | 316.22 |
| Oct 1, 2024 | 320.11 | -0.38 | -0.12% | 320.49 | 321.90 | 316.80 |
| Sep 30, 2024 | 321.99 | 1.04 | 0.32% | 320.95 | 322.95 | 318.43 |
| Sep 27, 2024 | 322.47 | 0.57 | 0.18% | 321.90 | 327.73 | 320.45 |
| Sep 26, 2024 | 318.79 | 5.09 | 1.62% | 313.70 | 319.58 | 312.95 |
| Sep 25, 2024 | 312.63 | -15.57 | -4.74% | 328.20 | 328.55 | 312.01 |
| Sep 24, 2024 | 330.85 | -2.10 | -0.63% | 332.95 | 335.20 | 330.37 |
| Sep 23, 2024 | 335.43 | -3.02 | -0.89% | 338.45 | 338.92 | 333.00 |
| Sep 20, 2024 | 337.23 | 2.18 | 0.65% | 335.05 | 338.86 | 333.70 |
| Sep 19, 2024 | 335.89 | -0.82 | -0.24% | 336.71 | 338.49 | 334.55 |
| Sep 18, 2024 | 332.64 | -0.59 | -0.18% | 333.23 | 338.68 | 329.99 |
| Sep 17, 2024 | 332.75 | -0.56 | -0.17% | 333.31 | 334.19 | 330.95 |
| Sep 16, 2024 | 335.20 | 0.79 | 0.24% | 334.41 | 337.28 | 332.71 |
| Sep 13, 2024 | 332.30 | 5.71 | 1.75% | 326.59 | 334.26 | 326.59 |
| Sep 12, 2024 | 329.98 | 0.29 | 0.09% | 329.69 | 331.89 | 326.22 |
| Sep 11, 2024 | 329.64 | 2.09 | 0.64% | 327.55 | 330.54 | 320.23 |
| Sep 10, 2024 | 328.74 | 2.29 | 0.70% | 326.45 | 329.13 | 322.27 |
| Sep 9, 2024 | 325.75 | 3.48 | 1.08% | 322.27 | 327.64 | 320.04 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Amgen Company profile
About Amgen, Inc.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Amgen, Inc. revenues increased 2% to $25.98B. Net income decreased 19% to $5.89B. Revenues reflect Other revenues segment increase of 42% to $1.68B, Prolia segment increase of 18% to $3.25B, ROW segment increase of 12% to $7.01B, Other revenues segment increase of 42% to $1.68B. Net income was offset by Research and development increase of 15% to $4.82B (expense), Other increase of 3% to $194M (expense).
Equity composition
Common Stock $.0001 Par, 4/11, 2.75B auth., 929,730,507 issd. Insiders own 0.12% . IPO 5/87, 2M shares @ $34 by Paine Webber. 9/91, 3-for-1 split; 11/99, 3/99, 8/95, 7/90, 2-for-1 splits. 7/02, Company acquired Immunex Corp. @ $4.50/share and 0.44 shs. (242,916,735 shs. issd.).
| Industry: | Pharmaceuticals (NEC) |
One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US
News
September US Non-Farm Payrolls Preview
Kyle Rodda, Senior Market Analyst at Capital.com, previews the US Non-Farm Payrolls report for September. The article discusses market expectations of a stable labor market with 150,000 new jobs, an unchanged unemployment rate of 4.2%, and steady annual wage growth at 3.8%. It also highlights potential rate cuts by the Federal Reserve, revisions to past payroll data, and the reaction of various markets such as the US Dollar, S&P 500, and gold.
07:59, 2 October 2024
Market of the Month - Gold, an overview
In 2024, gold has been on an upward trajectory, hitting high after high as global markets face ongoing challenges. This precious metal, long seen as a safe haven, has been proving its worth, drawing attention from traders around the world as its bullish surge continues.
06:00, 30 September 2024
RBA Preview: Rates to remain unchanged with inflation-fighting still the focus
RBA Governor Michelle Bullock emphasizes inflation challenges for Australia's economy, citing supply shocks and demand-supply imbalances. Discover insights on CPI trends, interest rates, and the central bank's strategy for managing price pressures in 2024.
12:27, 20 September 2024
BoE Preview: no change expected but forward guidance will be key
The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.
14:53, 19 September 2024
FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion
Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.
11:30, 19 September 2024
Bank of Japan Preview
The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.
09:40, 17 September 2024
FOMC Decision Preview
As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.
09:48, 16 September 2024People also watch
Still looking for a broker you can trust?
Join the 650,000+ traders worldwide that chose to trade with Capital.com